Evidence map›Paper›PMID 11874859›Full record

ArticleClinical and diagnostic laboratory immunology2002

Differential modulation of surface and intracellular protein expression by T cells after stimulation in the presence of monensin or brefeldin A.

Nancy J O'Neil-Andersen, David A Lawrence

Open access · diamondAbstract read
In one paragraph

Article in Clinical and diagnostic laboratory immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Influenza-Induced CD103ImmunoHorizons · 2022
    Article
  14. Article
  15. Lymphostatin, a virulence factor of attaching and effacingFrontiers in cellular and infection microbiology · 2022
    Article
  16. Review
  17. Review
  18. Viruses · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nancy J O'Neil-AndersenWadsworth Center, New York State Department of Health, Albany, New York 12201-0509, USA.
David A Lawrence
New York State Department of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracellular cytokine staining is an increasingly popular analytical tool that can be used to define the profile of cytokines in various disease states. One important requirement for this assay is the inclusion of a protein transport inhibitor in stimulated cell cultures to trap the cytokine, thus allowing a brighter signal. Two compounds commonly used for this purpose are brefeldin A (BFA) and monensin (MN). Flow cytometry was used to assess the differential effects of BFA and MN on surface CD3, -4, -8, and -69 expression and the intracellular expression of gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) following stimulation with phorbol myristate acetate and ionomycin. We found that BFA blocked the majority of CD3(+) cells from expressing surface CD69, but BFA did not inhibit intracellular CD69 expression. MN did not significantly inhibit surface CD69 expression. With regard to lymphocyte marker expression following activation, surface CD4 expression was significantly downregulated; however, less downregulation was observed with BFA treatment than with MN treatment. Analyzing intracellular cytokine expression, BFA trapped a greater percentage of TNF-alpha inside activated cells than MN. An analysis of the cytokine concentration in culture supernatants indicated that cells treated with MN released TNF-alpha and IFN-gamma from the cells, while the BFA-treated cells released IFN-gamma only. With prolonged (18-h) stimulation, the cells treated with MN were less viable than those treated with BFA. We conclude that the choice of a protein transport inhibitor is an important variable in this assay. When developing this method as a tool for clinical immunology laboratory analysis, investigators should consider the differential effects of BFA and MN on results.

Indexed as

AdultAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, SurfaceBiomarkersBrefeldin ACD69 AntigensCells, CulturedCell SurvivalCytokinesFemaleHumansIonophoresLectins, C-TypeMaleMiddle AgedAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, SurfaceBiomarkersBrefeldin ACD69 AntigensCytokinesIonophoresLectins, C-TypeMonensinProtein Synthesis Inhibitors

Identifiers

PMID11874859
PMCPMC119934
OpenAlexW2171512908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.